Compare Cassava Sciences Inc (FLNA) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Palo Alto Networks Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Palo Alto Networks Inc trades at $403.2 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 8420.3× Cassava Sciences Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Palo Alto Networks Inc for 82 Days on average.
| FLNA | PANW | |
|---|---|---|
Market Cap | $39.40M | $331.76B |
Volume | 759,018 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $4.64 | $419.91 |
52-Week Low | $0.68 | $141.67 |
Typical Hold Time | 37 Days | 82 Days |
Enterprise Value | -$43.28M | $331.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Palo Alto Networks (PANW) trades at $405.41, down 3.45% today but remains near recent highs, supported by strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth is robust, climbing from $5.5B in 2022 to $9.2B in 2025, though net margins have fluctuated. Positive sentiment is driven by AI-driven cybersecurity demand and platformization strategy gains.
Outlook: PANW offers growth exposure to the expanding cybersecurity market, with AI integration as a key catalyst. Risks include premium valuation multiples, rising costs, and competitive pressures. Analyst consensus is strongly bullish with a $398.70 price target, but investors should weigh high P/S and EV/EBITDA ratios against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
